A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Summary

This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2

Timeline

Start

2023-04-24

Primary completion

2025-07-15

Completion

2025-08-25

Drugs

Indications